SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-expected third-quarter report and managements upbeat 2027 outlook have driven CLFs sharp rally, with bullish traders focused on improved steel pricing and possible short covering. Others question whether the outlook can overcome the companys debt and execution concerns, and some view the move as a sell-the-news bounce.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade to Buy after a sharp selloff fueled hopes of a rebound, but traders debated whether the upgrade could overcome ongoing financing concerns, especially as the rally faded. Bulls point to AI demand, customer commitments and Nvidias support, while bears remain focused on CoreWeaves heavy debt burden and borrowing costs.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The FDAs early expansion of ANKTIVA plus BCG to papillary-only BCG-unresponsive bladder cancer, alongside long-term data showing durable responses, is driving discussion about a larger patient market and future sales. Traders are puzzled by the share-price decline despite the positive developments, debating a sell-the-news reaction and broader biotech weakness versus unverified claims of short-selling or options-related pressure.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are under heavy pressure amid IPO lockup-related selling concerns and a broader AI and semiconductor pullback, with traders also questioning the companys valuation, growth, and ability to scale. Bears expect further downside as more shares become eligible for sale, while bulls view the selloff as excessive and are averaging in.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are under pressure amid a sharp pullback, with traders pointing to repeated insider sales and a reported DBS downgrade as potential reasons for the weakness; some also cite broader Indonesia and Southeast Asia market concerns. Bulls argue the selling was planned and the business remains strong, while bears see insider selling and weak price action as warning signs.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons advance is drawing attention after Morgan Stanley named it a top pick, citing AWS growth, AI opportunities and warehouse automation as potential catalysts. Traders are broadly bullish on the move, though some remain cautious about heavy AI spending and whether the shares can sustain gains ahead of earnings.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, supporting a planned FDA resubmission. Traders are broadly reacting positively, while debating short-squeeze potential and flagging dizziness and sharp price swings as concerns.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Sharp post-IPO selling and volatile trading dominate the discussion, with traders pointing to lockup-related supply, bearish analyst coverage, and weakness across nuclear stocks as possible pressures. Bulls are treating the pullback as an opportunity, citing Amazons backing and X-energys potential role in meeting future data-center power demand, while others stress that reactor commercialization remains years away.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff alongside other AI neocloud stocks, as traders debate financing costs and whether the sectors growth can justify its heavy capital needs. Some see the rebound and analyst support as a buying opportunity, while others call it a short-lived bounce and expect more pressure.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Attention centers on the FDA-cleared expansion of Alpha Taus REGAIN trial for recurrent glioblastoma and anticipated clinical data at the SNO meeting. Traders are bullish on early tumor-control findings and the broader pipeline, though some note the evidence comes from a small initial cohort.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can India’s Sugar Stocks Regain Momentum? Output Is Likely To Rise 18%, But Ethanol Woes Cloud Outlook

Equity

Relaxed export rules and increased diversion for ethanol production could partially offset challenges surrounding pricing. Key players like Balrampur Chini and EID Parry remain on investor watchlists

Budget 2025: 8 fertilizer, sugar stocks outperform Nifty significantly since Feb's Interim Budget; Deepak Fertilizers turns multibagger.

Eight stocks from the sugar and fertilizer sectors have outperformed the Nifty since the February 2024 interim budget, defying a 6% drop in India's benchmark index post the July budget. Notably, Deepak Fertilizers has turned into a multibagger, delivering 50% returns. Other notable stocks include Coromandel International, Paradeep Phosphates, and Bannari Amman Sugars, all posting strong gains during this period.

Bannari Amman Sugars Ltd. engages in the manufacture and marketing of sugar and its by-products. It operates through the following segments: Sugar, Power, Distillery, and Granite Products. The Sugar segment manufactures sugar and related products. The Power segment engages in co-generation of power and wind power. The Distillery segment produces alcohol and liquor. The Granite Products segment manufactures granite slabs, tiles and bio products. The company was founded on December 1, 1983 and is headquartered in Coimbatore, India.

Bannari Amman Sugars Ltd.

Neutral Sentiment

India’s sugar stocks could be headed for a crucial season. The country’s sugar output is projected to rise nearly 18% in 2025-26, even as ethanol faces pricing pressures and the looming threat of tariffs on potential imports.&nbsp;With the government’s focus on pushing ethanol-blended fuel and cane pricing in focus, the next few months will help determine if the sugar sector can regain its sweet spot.A few sugar stocks have been gaining traction on investors' radar from this space. <a href="https://stocktwits.com/symbol/EIDPARRY.NSE">EID Parry (India)</a> has rallied 45% in the last six months, <a href="https://stocktwits.com/symbol/BALRAMCHIN.NSE">Balrampur Chini</a>, and <a href="https://stocktwits.com/symbol/DALMIASUG.NSE">Dalmia Bharat</a> have clocked in over 25% gains.&nbsp;Other notable companies include <a href="https://stocktwits.com/symbol/BAJAJHIND.NSE">Bajaj Hindusthan Sugar</a> and <a href="https://stocktwits.com/symbol/RENUKA.NSE">Shree Renuka Sugars</a>.Strong Output ForecastIndia’s sugar output is projected to surge nearly 18% to 34.9 million tonnes in the 2025–26 season, according to the Indian Sugar and Bio-energy Manufacturers Association (ISMA). Additionally, sugar diverted for ethanol production is expected to rise to 5 million tonnes, compared with 3.5 million tonnes in the current season.Ethanol from Sugar: The ChallengesEthanol is made from sugarcane, maize, and grains. It is a clear, colorless alcohol that is commonly used as a blending agent with petrol to reduce vehicle emissions.In August 2024, the Indian government permitted sugar mills to produce ethanol from cane juice, syrup, and B‑heavy molasses, a byproduct with higher sucrose levels. The move was expected to support the goal of 20% ethanol blending into petrol by 2025‑26.The original goal of achieving 20% blending (E20) by 2030 was brought forward to 2025 and was met in March 2025. Now the Indian government is aiming to blend 30% ethanol in petrol by 2030.However, the sugar industry hasn’t yet benefited from the success of ethanol blending as the sector’s share in the national ethanol program has plunged from 73% to 28% in just two years.Capacity Present, But Not Enough UtilizationIndia has the capacity to produce 952 crore litres of ethanol per year, with the potential to divert 40 lakh tonnes of sugar. And still, only 32 lakh tonnes are expected to be used this year, which highlights the underutilization in the sector.The National Federation of Cooperative Sugar Factories (NFCSF) said sugar-based ethanol supply is expected to fall from 369 crore litres in 2022-23 to 250 crore litres in 2024-25, as stagnant ethanol prices lag behind rising sugarcane costs, making direct sugar sales more profitable.The Tariff Overhang&nbsp;The ongoing tariff-related challenges could act as another stumbling block.&nbsp;Last month, the Indian Sugar and Bio-energy Manufacturers Association (ISMA) objected to the proposed talks on permitting ethanol imports under the India-US trade framework, warning that it could hinder payment of the Fair and Remunerative Price (FRP) to sugarcane farmers and result in underutilization of domestic ethanol production capacity.Sugar Stocks: Mixed Moves In 2025Using Stocktwits data, we see a mixed 2025 so far for the sugar sector, with retail investors primarily in a wait-and-watch mode. The Nifty Commodities index, by comparison, is up around 8% in the same period.<img src="https://news.stocktwits-cdn.com/G_Nd_LY_indian_sugar_stocks_ytd_performance_png_a7a1d4af27.webp" alt="GNdLY-indian-sugar-stocks-ytd-performance.png">Given below is the Q4 FY25 financial data for five key sugar companies.<img src="https://news.stocktwits-cdn.com/1i_Tlx_q4_fy25_earnings_data_png_6ffd038376.webp" alt="1iTlx-q4-fy25-earnings-data.png">The Next Triggers: What Investors Are WatchingAny upward revision in ethanol pricing is likely to boost sentiment for sugar stocks. Additionally, clarity on import pricing for ethanol during the upcoming US-India trade discussions will be crucial.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Current Price	3,300.00
Prev Close	3,307.70
Open	3,256.00
Dividend Yield	0.33%
50-Day Moving Average	3,532.29
Beta	-0.09
Avg. Volume	1,333.67
PE Ratio	34.25

52-Week High	4,338.00
52-Week Low	3,196.50
Market Capitalization	41.61B
EPS (Annual)	117.96
Price to Book	2.18
Revenue Per Employee	8.4M

Feed

News

Sentiment

Fundamentals

Info

BANARISUG.NSE Fundamentals